What is the recommended management and prophylaxis for respiratory syncytial virus (RSV) infection in infants and high‑risk children?

RSV Prophylaxis and Management in Infants and High-Risk Children

All infants under 8 months of age born during or entering their first RSV season should receive nirsevimab, a single-dose long-acting monoclonal antibody, administered from October through March in most of the continental United States. 1

Universal Prophylaxis with Nirsevimab (First-Line, 2023)

The 2023 ACIP guidelines represent a paradigm shift from risk-based to universal prophylaxis:

Primary Recommendations:

• All infants <8 months born during or entering their first RSV season: Single intramuscular dose of nirsevimab 1
• High-risk children 8-19 months entering their second RSV season: Single dose of nirsevimab 1
• Timing: October through end of March (based on pre-COVID patterns) 1

Key Advantage Over Previous Standard:

Nirsevimab requires only one dose per season versus palivizumab's five monthly doses, and extends protection to all infants rather than just the <5% with specific high-risk conditions 1. This addresses the critical gap that 79% of RSV hospitalizations occur in previously healthy term infants with no underlying conditions 1.

High-Risk Groups Requiring Special Attention

Children aged 8-19 months entering their second RSV season qualify for nirsevimab if they have:

• Chronic lung disease of prematurity requiring medical therapy (oxygen, bronchodilators, diuretics, or corticosteroids) within 6 months before RSV season 2
• Hemodynamically significant congenital heart disease 2
• Severe immunodeficiency 3
• Neuromuscular impairment 3
• Cystic fibrosis 3
• Down syndrome 3

Palivizumab: Legacy Agent (Still Relevant in Limited Scenarios)

While nirsevimab is now the standard, palivizumab remains FDA-approved and may be used when nirsevimab is unavailable:

Dosing:

• 15 mg/kg intramuscularly
• Five monthly doses beginning November/December 2
• Continue throughout season regardless of age milestones 2

Historical Efficacy Data:

• 72% reduction in RSVH for preterm infants <36 weeks 4
• 65% reduction for bronchopulmonary dysplasia 4
• 53% reduction for hemodynamically significant CHD 4

Prematurity-Based Risk Stratification (Historical Context)

The older palivizumab guidelines used gestational age cutoffs that are now superseded by universal nirsevimab recommendations, but remain relevant for understanding risk:

• ≤28 weeks gestation: Prophylaxis throughout first RSV season (first 12 months of life) 2
• 29-32 weeks gestation: Prophylaxis up to 6 months of age 2
• 32-35 weeks gestation: Only if <6 months at RSV season start AND ≥2 risk factors present:
  • Child care attendance
  • School-aged siblings
  • Environmental air pollutants
  • Congenital airway abnormalities
  • Severe neuromuscular disease 2

Critical Pitfalls to Avoid

1. Don't stop prophylaxis mid-season when infant reaches 6 or 12 months—continue through entire RSV season once initiated 2

2. Don't rely on single risk factors for 32-35 week preterm infants—risk is additive and requires ≥2 factors 2

3. Don't use tobacco smoke exposure as sole justification for prophylaxis—this is a modifiable risk factor that families must control 2

4. Regional timing varies: Southern U.S. experiences earlier RSV seasons; adjust administration timing accordingly 2

Supportive Management (No Specific Antivirals)

For active RSV infection, treatment remains supportive only:

• Oxygen supplementation if SpO2 <90% 2
• Airway suctioning as needed 2
• Monitor work of breathing in premature/low birth weight infants 2

Ribavirin has conflicting evidence (moderate strength) and is not routinely recommended 4. Consider only in:

• High-risk infants with serious clinical course 5
• Post-transplant patients (stem cell or organ with rejection episodes) with mild-moderate RSV pneumonia, combined with IV immunoglobulin 5

Preventive Measures for All High-Risk Infants

Beyond immunoprophylaxis:

• Avoid crowds and group child care during RSV season 2
• Strict hand hygiene for all contacts 2
• Zero tobacco smoke exposure (non-negotiable) 2
• Influenza vaccination for infant (≥6 months) and all contacts 2

Future Landscape

Maternal RSV vaccines and additional long-acting monoclonals (clesrovimab) are in development 6, 7, but nirsevimab remains the current evidence-based standard for infant prophylaxis as of 2023 1.